New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export AZN’s income statement to Excel — free account
AstraZeneca PLC
AZNHealthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +23.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
175.62
0.17
+0.10%
Follow AZN
Alert me
Ratios over time FY16 to FY25
Returns on capital
ROIC was 12.2% in FY25, the highest of these ten years.
ROEROIC
| FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 19.9% | 18.0% | 14.0% | 9.3% | 21.1% | 0.4% | 8.6% | 15.6% | 17.6% | 22.8% |
| ROIC | 11.1% | 7.7% | 7.8% | 7.1% | 11.9% | 1.0% | 4.0% | 8.4% | 9.8% | 12.2% |
Debt
Net debt is 1.13× a year’s EBITDA. Debt is 0.57× equity, against 1.36× in FY18.
Debt / equityNet debt / EBITDA
| FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / equity | 1.0× | 1.1× | 1.4× | 1.2× | 1.3× | 0.8× | 0.8× | 0.7× | 0.7× | 0.6× |
| Net debt / EBITDA | 1.5× | 2.0× | 1.8× | 1.7× | 1.4× | 3.1× | 2.4× | 1.6× | 1.4× | 1.1× |
Cash cycle, in days
Customers pay in 102 days, inventory is held 225 days and suppliers are paid in 868. Suppliers fund 541 days of working capital.
Days to pay suppliersDays to be paid
| FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash cycle | −642 | −638 | −640 | −710 | −709 | −192 | −330 | −640 | −514 | −541 |
| Days to pay suppliers | 928 | 984 | 950 | 1037 | 1087 | 556 | 561 | 988 | 803 | 868 |
| Days to be paid | 79 | 90 | 96 | 91 | 101 | 101 | 93 | 108 | 100 | 102 |
Per share, from FY16
Since FY16, per share: free cash flow has grown 8.91% a year; revenue has grown 8.50% a year; book value has grown 10.1% a year.
Free cash flowRevenueBook value
| FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | 1.0× | 1.0× | 1.1× | 0.8× | 0.9× | 1.2× | 1.9× | 1.7× | 1.8× | 2.2× |
| Revenue | 1.0× | 1.0× | 1.0× | 1.0× | 1.1× | 1.5× | 1.6× | 1.6× | 1.9× | 2.1× |
| Book value | 1.0× | 1.0× | 0.8× | 0.9× | 0.9× | 2.1× | 1.8× | 1.9× | 2.0× | 2.4× |
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
26.58 | 28.59 | 34.41 | 63.76 | 386.17 | 41.06 | 95.28 | 44.68 | 28.82 | 19.94 |
Piotroski F-Score |
9 | 6 | 7 | 7 | 5 | 7 | 6 | 4 | 3 | 6 |
P/S ratio |
4.63 | 3.73 | 4.49 | 4.76 | 4.39 | 4.98 | 5.39 | 4.36 | 3.87 | 3.05 |
Altman Z-Score |
3.52 | 2.77 | 2.69 | 2.66 | 1.94 | 2.31 | 2.25 | 1.90 | 1.80 | 1.66 |
P/FCF ratio |
30.83 | 27.05 | 29.43 | 26.51 | 37.65 | 40.77 | 50.11 | 26.76 | 25.41 | 20.99 |
Altman Z″-Score (non-manufacturers) |
1.80 | 1.30 | 0.90 | 0.65 | 0.97 | 1.03 | 0.52 | 0.92 | 0.85 | 1.12 |
Beneish M-Score |
(2.51) | (2.59) | (2.58) | (2.75) | (2.20) | (2.40) | (2.59) | (2.54) | (2.48) | (2.74) |
P/Operating CF |
116.08 | 69.36 | 86.44 | 88.08 | 115.85 | 73.70 | 95.56 | 43.27 | 87.10 | 35.77 |
P/B ratio |
5.58 | 4.93 | 5.25 | 5.70 | 4.18 | 8.47 | 9.00 | 6.85 | 5.22 | 4.21 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
5.00 | 4.16 | 4.96 | 5.25 | 5.01 | 5.41 | 5.85 | 4.95 | 4.45 | 3.52 |
EV/EBITDA |
15.09 | 13.47 | 16.73 | 25.22 | 24.73 | 17.34 | 21.34 | 15.32 | 14.91 | 11.16 |
EV/Operating CF |
20.16 | 18.95 | 21.96 | 23.76 | 31.46 | 30.02 | 48.06 | 41.79 | 27.97 | 19.54 |
EV/FCF |
33.32 | 30.16 | 32.49 | 29.25 | 43.00 | 44.33 | 54.42 | 30.42 | 29.28 | 24.25 |
Quick Ratio |
0.72 | 0.74 | 0.64 | 0.67 | 0.74 | 0.76 | 0.68 | 0.72 | 0.62 | 0.72 |
Current Ratio |
0.94 | 0.93 | 0.82 | 0.86 | 1.16 | 0.96 | 0.86 | 0.96 | 0.80 | 0.87 |
Net Debt/EBITDA |
1.13 | 1.39 | 1.58 | 2.36 | 3.07 | 1.39 | 1.69 | 1.85 | 1.97 | 1.50 |
Debt/Assets |
24.39% | 27.72% | 27.19% | 29.31% | 28.28% | 29.52% | 28.60% | 31.51% | 28.11% | 26.88% |
Debt/Equity |
0.57 | 0.71 | 0.70 | 0.76 | 0.76 | 1.26 | 1.20 | 1.36 | 1.07 | 1.01 |
Asset Turnover |
0.54 | 0.53 | 0.46 | 0.44 | 0.43 | 0.42 | 0.40 | 0.36 | 0.36 | 0.38 |
Operating CF/Net income |
1.43 | 1.69 | 1.74 | 2.98 | 53.24 | 1.50 | 2.22 | 1.21 | 1.19 | 1.18 |
Capex/Depreciation |
(1.00) | (0.66) | (0.62) | (0.34) | (0.24) | (0.49) | (0.09) | 0.26 | (0.05) | (0.34) |
Interest Coverage |
8.11 | 5.74 | 5.04 | 2.79 | 0.81 | 3.95 | 2.04 | 2.39 | 2.44 | 3.54 |
| 22.83% | 17.58% | 15.63% | 8.61% | 0.41% | 21.14% | 9.32% | 14.05% | 18.02% | 19.89% | |
| 9.38% | 6.86% | 6.03% | 3.26% | 0.13% | 4.99% | 2.19% | 3.48% | 4.77% | 5.71% | |
ROIC |
12.15% | 9.77% | 8.45% | 3.99% | 1.05% | 11.86% | 7.06% | 7.78% | 7.69% | 11.12% |
Return on Tangible Assets |
92.38% | 85.66% | 152.15% | 68.40% | 0.87% | 42.68% | 26.00% | 32.07% | 68.48% | 72.08% |
Average Days of Receivables |
101.50 | 100.11 | 107.98 | 92.60 | 100.54 | 101.28 | 90.50 | 95.52 | 89.90 | 79.33 |
Research and Development Expense of Revenue |
24.23% | 25.12% | 23.87% | 22.01% | 26.02% | 22.51% | 24.85% | 26.85% | 25.63% | 25.61% |
Selling, General and Administrative Expense of Revenue |
34.92% | 37.97% | 43.12% | 42.74% | 41.91% | 43.93% | 49.30% | 46.91% | 46.93% | 42.34% |
Intangible Assets out of Total Assets |
0.52 | 0.56 | 0.57 | 0.61 | 0.59 | 0.49 | 0.53 | 0.56 | 0.60 | 0.63 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
(0.13) | (0.19) | (0.18) | (0.17) | (0.24) | (0.24) | (0.24) | (0.32) | (0.39) | (0.46) |
Graham Number |
68.35 | 51.92 | 46.86 | 33.95 | 13.68 | 25.69 | 16.36 | 20.59 | 26.53 | 28.71 |
Earnings Yield |
3.76% | 3.50% | 2.91% | 1.57% | 0.26% | 2.44% | 1.05% | 2.24% | 3.47% | 5.02% |
Free Cash Flow Yield |
3.24% | 3.70% | 3.40% | 3.77% | 2.66% | 2.45% | 2.00% | 3.74% | 3.94% | 4.76% |
Revenue per Share |
37.90 | 34.89 | 29.57 | 28.65 | 26.39 | 20.29 | 18.74 | 17.43 | 17.74 | 18.18 |
Operating CF per Share |
9.40 | 7.65 | 6.68 | 6.34 | 4.21 | 3.66 | 2.28 | 2.07 | 2.83 | 3.28 |
Capex per Share |
(3.71) | (2.84) | (2.17) | (1.19) | (1.13) | (1.18) | (0.27) | 0.77 | (0.13) | (0.64) |
Free Cash Flow per Share |
5.69 | 4.81 | 4.51 | 5.15 | 3.08 | 2.48 | 2.02 | 2.84 | 2.70 | 2.64 |
Cash per Share |
3.76 | 3.68 | 3.92 | 4.19 | 4.57 | 6.20 | 4.81 | 4.69 | 3.62 | 4.69 |
Shareholders Equity per Share |
31.43 | 26.37 | 25.28 | 23.94 | 27.71 | 11.92 | 11.22 | 11.08 | 13.15 | 13.18 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
31.43 | 26.37 | 25.28 | 23.94 | 27.71 | 11.92 | 11.22 | 11.08 | 13.15 | 13.18 |
Free Cash Flow |
8,819.00 | 7,453.00 | 6,990.00 | 7,966.00 | 4,363.00 | 3,250.00 | 2,622.00 | 3,597.00 | 3,417.00 | 3,340.00 |
Working Capital |
(1,894.00) | (2,039.00) | (5,488.00) | (3,700.00) | 3,650.00 | (763.00) | (2,554.00) | (701.00) | (3,233.00) | (1,994.00) |
Capital Expenditures |
(5,756.00) | (4,408.00) | (3,355.00) | (1,842.00) | (1,600.00) | (1,549.00) | (347.00) | 979.00 | (161.00) | (805.00) |
Net Current Asset Value |
(36,632.00) | (37,337.00) | (36,899.00) | (36,832.00) | (39,832.00) | (31,547.00) | (31,218.00) | (31,016.00) | (33,562.00) | (32,595.00) |
EV/EBIT |
21.38 | 22.47 | 27.72 | 62.02 | 177.64 | 27.91 | 48.80 | 32.30 | 27.21 | 16.52 |
Capex to Sales |
0.10 | 0.08 | 0.07 | 0.04 | 0.04 | 0.06 | 0.01 | (0.04) | 0.01 | 0.04 |
Price to Operating Income |
19.78 | 20.16 | 25.11 | 56.22 | 155.56 | 25.67 | 44.94 | 28.41 | 23.62 | 14.30 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.44 | 0.65 | 0.57 | 0.64 | 0.71 | 0.38 | 0.49 | 0.51 | 0.40 | 0.34 |
Cash ROIC |
10.71% | 9.88% | 9.61% | 11.09% | 5.77% | 7.48% | 6.83% | 9.20% | 8.75% | 8.48% |
Accounts Receivable Turnover |
3.77 | 3.81 | 3.69 | 4.11 | 4.23 | 3.96 | 4.12 | 3.90 | 4.27 | 3.83 |
Accounts Payable Turnover |
0.45 | 0.46 | 0.40 | 0.65 | 0.72 | 0.36 | 0.37 | 0.40 | 0.39 | 0.37 |
Inventory Turnover |
1.80 | 1.91 | 1.63 | 1.81 | 1.91 | 1.47 | 1.62 | 1.67 | 1.61 | 1.84 |
Average Days of Payables |
867.79 | 803.34 | 987.73 | 560.86 | 555.79 | 1,087.29 | 1,037.44 | 949.55 | 984.01 | 927.63 |
Days of Inventory on Hand |
225.08 | 189.10 | 239.45 | 138.42 | 263.63 | 277.18 | 236.83 | 213.71 | 256.55 | 206.47 |
Average Receivables |
15,583.00 | 14,191.50 | 12,402.00 | 10,779.50 | 8,846.50 | 6,716.00 | 5,913.50 | 5,657.00 | 5,266.00 | 6,004.00 |
Average Payables |
23,872.50 | 22,419.50 | 20,707.00 | 18,989.00 | 17,361.50 | 14,886.00 | 13,414.00 | 12,241.00 | 11,063.50 | 11,074.50 |
Average Inventory |
5,922.50 | 5,356.00 | 5,061.50 | 6,841.00 | 6,503.50 | 3,608.50 | 3,041.50 | 2,962.50 | 2,684.50 | 2,238.50 |
Average Assets |
109,054.50 | 102,577.00 | 98,801.00 | 100,923.00 | 86,046.00 | 64,053.00 | 61,014.00 | 62,002.50 | 62,940.00 | 61,291.00 |
Average Common Equity |
44,795.00 | 40,018.50 | 38,112.00 | 38,172.50 | 27,462.50 | 15,117.00 | 14,320.00 | 15,343.00 | 16,655.50 | 17,589.00 |
Columns are period end dates · fundamentals updated Nov 18, 2026